Alkermes plc. (ALKS) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $26.50M; Long-term Debt, Excluding Current MaturitiesUSD $1.48B; Long-term DebtUSD $1.52B; Long-Term Debt, Maturity, Year OneUSD $26.50M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $26.50M; Long-term Debt, Excluding Current MaturitiesUSD $1.48B; Long-term DebtUSD $1.52B; Long-Term Debt, Maturity, Year OneUSD $26.50M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2024-09-30: Long-term Debt, Current MaturitiesUSD $3.00M; Long-term Debt, Excluding Current MaturitiesUSD $285.82M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
Alkermes plc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.50M | $1.48B | $1.52B | $26.50M | $40.56M | $45.25M | $45.25M | $1.35B | $19.88M | $1.50B | $11.40M |
| 2026-03-31 | $26.50M | $1.48B | $1.52B | $26.50M | $40.56M | $45.25M | $45.25M | $1.35B | $19.88M | (m) | $12.00M |
| 2025-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2024-09-30 | $3.00M | $285.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $3.00M | $286.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $3.00M | $287.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $3.00M | $287.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $3.00M | $288.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $3.00M | $289.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $3.00M | $289.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $3.00M | $290.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.00M |
| 2022-09-30 | $3.00M | $290.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $3.00M | $291.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $3.00M | $292.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $3.00M | $292.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.30M |
| 2021-09-30 | $3.00M | $293.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $3.00M | $294.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $3.00M | $294.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $2.84M | $272.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.00M |
| 2020-09-30 | $2.84M | $272.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $2.84M | $273.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $2.84M | $273.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $2.84M | $274.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.50M |
| 2019-09-30 | $2.84M | $274.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $2.84M | $275.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $2.84M | $275.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $2.84M | $276.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.00M |
| 2018-09-30 | $2.84M | $277.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $2.84M | $277.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $2.84M | $278.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.00M | $278.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.80M |
| 2017-09-30 | $3.00M | $278.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $3.00M | $279.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $3.00M | $280.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $3.00M | $280.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $283.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $3.00M | $282.58M | $285.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $63.91M | $283.12M | $347.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $64.83M | $283.66M | $348.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $65.74M | $284.21M | $349.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.30M |
| 2015-09-30 | $66.71M | $286.51M | $353.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $6.75M | $348.06M | $354.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $6.75M | $349.64M | $356.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $6.75M | $349.01M | $355.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.40M |
| 2014-09-30 | $6.75M | $352.80M | $359.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $6.75M | $354.38M | $361.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $6.75M | $355.96M | $362.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $6.75M | $357.54M | $364.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.30M |
| 2013-09-30 | $6.75M | $359.12M | $365.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $6.75M | $360.69M | $367.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $6.75M | $362.26M | $369.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.60M |
| 2012-12-31 | $6.75M | $362.35M | $369.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.20M |
| 2012-09-30 | $6.75M | $363.85M | $370.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.40M |
| 2012-06-30 | $3.10M | $441.08M | $444.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $3.10M | $441.36M | $444.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $3.10M | $441.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $2.33M | $441.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |